Drugs and Devices

FDA approves Perjeta for late-stage breast cancer

On June 8, the U.S. Food and Drug Administration (FDA) approved Perjeta (pertuzumab), a new anti-HER2 therapy, to treat patients with HER2-positive late-stage breast cancer. Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares